The risks of using allogeneic cell lines for vaccine production: the example of Bovine Neonatal Pancytopenia

• Main Authors: Lindert Benedictus (Author), Charlotte R. Bell (Author)
• Format: Book
• Published: Taylor & Francis Group, 2017-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1476-0584; 1744-8395; 10.1080/14760584.2017.1249859
• Keywords: vaccine safety; vaccine production; alloantibody; allogeneic; alloimmune; bovine neonatal pancytopenia (bnp); major histocompatibility complex class i (mhc i); cell line; colostrum; hematopoietic; Internal medicine; RC31-1245
• Source: Expert Review of Vaccines, Vol 16, Iss 1, Pp 65-71 (2017)

Introduction: Bovine neonatal pancytopenia (BNP) is a hemorrhagic disease that emerged in calves across Europe in 2007. Its occurrence is attributed to immunization of the calf's mother with a vaccine produced using an allogeneic cell line. Vaccine-induced alloantibodies specific for major-histocompatibility class I antigens are transferred from the mother to the calf via colostrum, leading to profound depletion of peripheral blood and bone marrow cells that is often fatal. Areas covered: Pubmed and Web of Science were used to search for literature relevant to BNP and the use of allogeneic vaccine cell lines. Following a review of the pathology and pathogenesis of this novel condition, we discuss potential risks associated with the use of allogeneic vaccine cell lines. Expert commentary: Although BNP is associated with a specific vaccine, it highlights safety concerns common to all vaccines produced using allogeneic cell lines. Measures to prevent similar vaccine-induced alloimmune-mediated adverse events in the future are discussed.